https://www.selleckchem.com/pr....oducts/epacadostat-i
reening in the UK. Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED. In this retrospective review, consecutive patients with chronic stable TED (2 years), who had received ≥3 infusions of teprotumumab were included. All patients had measurements of proptosis, and calculation of the CAS and diplopia scores before and after therapy. Five-point strabismus scores were also calculated. Patien
Curtir
Comentario
Compartilhar
